ADCC	Antibody-dependent cellular cytotoxicity
ATRA	All-trans retinoic acid
BM	Bone marrow
CAR	Chimeric antigen receptor
CDC	Complement-dependent cytotoxicity
CG	Cytogenetics
CGS	Consensus Genomic Staging
dara	daratumumab
EZH2	enhancer of zeste homolog 2
f	female
HDACi	pan–histone deacetylase inhibitor
HS	Bone marrow stromal cell
ID	Initial diagnosis
Ig	Immunoglobulin
IMS	International Myeloma Society
IMWG	International Myeloma Working Group
ISS	International Staging System
LC	Light chain
MFI	Mean fluorescence intensity
m	male
MM	Multiple Myeloma
n.e.	not evaluated
NK	natural killer
n.s.	not significant
ORR	Overall response rate
pano	panobinostat
PB	Peripheral blood
PC	Plasma cell
PCL	Plasma cell leukemia
PD	Progressive disease
PE	Pleural effusion
pos	positive
SR	Standard risk
HR	High risk
Ys	Years